FDA Clears Venus Versa Pro System

Venus Concept, a medical aesthetic technology firm, has gained U.S. Food and Drug Administration 510(k) clearance for its Venus Versa Pro system, a multi-application platform for a number of aesthetic and cosmetic procedures.
 
Venus Versa is a modular, customizable, upgradeable system that supports 10 optional applicators utilizing Venus Concept’s (MP)², IPL, and NanoFractional RF technologies. The company said it can be configured to suit any practice’s needs by adding further applications as the practice grows or changes.
 
The new system incorporates proprietary advances in NanoFractional RF technologies for its dedicated skin resurfacing system, Venus VivaMD, for higher power and deeper skin penetration.
 
“This important clearance is a direct outcome of the new strategic plan we implemented earlier this year,” Rajiv De Silva, CEO of Venus Concept told the press. “Our new strategy has led us to prioritize the allocation of resources to our most promising growth opportunities and focus on continued innovation to accelerate our path to long-term, sustainable, profitability and growth. We anticipate that the Venus Versa Pro System will be an important contributor to revenue growth in 2024.”
 
“The Venus Versa Pro System once again demonstrates our commitment to continue to build upon our robust R&D pipeline,” added Hemanth Varghese, president and chief innovation and business officer of Venus Concept. “The advancements we are introducing in the Venus Versa Pro System, will provide superior, comprehensive technologies to support our existing and future customers, and address the growing demand for multi-modal solutions in aesthetics. Venus Versa has been one of the company’s best-selling products over the last 5 years with thousands of installations worldwide. We are confident that its new generation Venus Versa Pro System, can surpass the success of Venus Versa, offering our existing customer base an attractive upgrade option, as well as offering new customers a new standard of care to address nearly all their patient’s aesthetic concerns with one platform. We look forward to formally announcing our commercial launch in the coming weeks.”

Earlier this year, the company earned FDA clearance to market its AI.ME next-gen robotic tech for fractional skin resurfacing.